Table 3.
Baseline Characteristics of the 462 Participants With Microalbuminuria/Albuminuria Progression
| Progressors | Nonprogressors | P Value | |
|---|---|---|---|
| n | 94 | 368 | |
| Sex (male, %) | 42.6 | 53.5 | .057 |
| Age, y | 55.8 ± 9.09 | 53.3 ± 8.88 | .014 |
| Ever smoke, % | 27.7 | 26.9 | .883 |
| BMI, kg/m2 | 25.5 ± 4.32 | 25.0 ± 4.03 | .245 |
| WC (cm) | .095b | ||
| Males | 90.4 ± 13.6 | 88.4 ± 9.76 | |
| Females | 86.5 ± 10.5 | 84.3 ± 11.8 | |
| SBP, mm Hg | 132.4 ± 17.9 | 126.4 ± 17.8 | .004 |
| DBP, mm Hg | 77.6 ± 8.60 | 76.9 ± 8.62 | .509 |
| Hypertension, % | 78.7 | 59.2 | <.001 |
| Antihypertensive treatment, % | 75.5 | 54.3 | <.001 |
| ACEI/ARB, % | 68.1 | 41.8 | <.001 |
| DM duration, y | 13.7 ± 7.46 | 12.3 ± 7.76 | .123 |
| FPG, mmol/L | 8.39 ± 2.74 | 8.14 ± 2.44 | .388 |
| HbA1c, % | 8.61 ± 1.50 | 8.02 ± 1.34 | <.001 |
| Total cholesterol, mmol/L | 4.82 ± 1.00 | 4.78 ± 0.99 | .720 |
| TG,a mmol/L | 1.42 (1.02–1.81) | 1.17 (0.84–1.91) | .219 |
| HDL-C, mmol/L | 1.23 ± 0.34 | 1.24 ± 0.36 | .710 |
| LDL-C, mmol/L | 2.89 ± 0.93 | 2.84 ± 0.84 | .606 |
| Lipid-lowering treatment, % | 28.7 | 23.1 | .256 |
| Creatinine,a μmol/L | .023b | ||
| Males | 81.0 (72.5–91.5) | 79.0 (72.0–87.5) | |
| Females | 63.0 (56.0–72.3) | 89.9 (79.9–102.0) | |
| eGFRa | 85.0 (73.5–98.0) | 89.5 (79.2–100.6) | .010 |
| CKD stage, % | .199 | ||
| 1 | 40.4 | 47.8 | |
| 2 | 59.6 | 52.2 | |
| PEDF,a μg/mL | <.001b | ||
| M | 9.25 (8.35–10.45) | 8.68 (7.40–9.60) | |
| F | 8.85 (8.06–9.94) | 8.22 (6.91–9.73) | |
| CRP,a mg/L | 1.27 (0.70–3.84) | 1.03 (0.42–2.48) | .010 |
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DBP, diastolic BP; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides.
a
Log-transformed before analysis.
b
Sex-adjusted P value.